PMID- 16761012
OWN - NLM
STAT- MEDLINE
DCOM- 20070509
LR  - 20220330
IS  - 0955-9930 (Print)
IS  - 0955-9930 (Linking)
VI  - 19
IP  - 2
DP  - 2007 Mar-Apr
TI  - The effects of chronic phosphodiesterase-5 inhibitor use on different organ 
      systems.
PG  - 139-48
AB  - Phosphodiesterase-5 (PDE-5) inhibitors selectively inhibit PDE-5 enzymes that are 
      present in various tissues like penile tissue, platelets, vascular, and smooth 
      muscle tissue. The drug's actions on these tissues have lead to the successful 
      therapeutic use in patients suffering from conditions such as erectile 
      dysfunction (ED) and pulmonary hypertension. PDE-5 inhibitors (PDE-5i) act on the 
      erectile tissue causing penile smooth muscle relaxation and vasodilatation 
      leading to penile erection. In addition, in particular when used in conjunction 
      with prostaglandin inhibitors, PDE-5i cause vasodilatation in pulmonary 
      vasculature hence decreasing both the pulmonary arterial pressure and resistance. 
      PDE-5i have also shown to mildly decrease blood pressure, increase cardiac index, 
      and increase coronary blood flow in experimental animals as well as in human 
      studies. The Food and Drug Administration (FDA) has approved three PDE-5i for the 
      treatment of ED: sildenafil (Viagra), vardenafil (Levitra), and tadalafil 
      (Cialis) and one for pulmonary hypertension: sildenafil (Revatio). These agents 
      are highly selective for PDE-5 enzymes as compared to other subclasses of PDE 
      enzymes and have the almost identical pharmacological action but slightly 
      different pharmacokinetics. Only little data exist about long-term use of PDE-5i 
      and their effects on different organ system. This paper reviews the current 
      information available on chronic PDE-5 inhibitor use.
FAU - Schwarz, E R
AU  - Schwarz ER
AD  - Division of Cardiology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA. 
      schwarze@cshs.org
FAU - Kapur, V
AU  - Kapur V
FAU - Rodriguez, J
AU  - Rodriguez J
FAU - Rastogi, S
AU  - Rastogi S
FAU - Rosanio, S
AU  - Rosanio S
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060608
PL  - England
TA  - Int J Impot Res
JT  - International journal of impotence research
JID - 9007383
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - EC 3.1.4.35 (3',5'-Cyclic-GMP Phosphodiesterases)
SB  - IM
MH  - 3',5'-Cyclic-GMP Phosphodiesterases/*antagonists & inhibitors
MH  - Age Factors
MH  - Animals
MH  - Blood Platelets/drug effects
MH  - Cerebrovascular Circulation/drug effects
MH  - Erectile Dysfunction/*drug therapy/etiology
MH  - Gastrointestinal Tract/drug effects
MH  - Heart/drug effects
MH  - Humans
MH  - Lung/drug effects
MH  - Male
MH  - Myocardial Ischemia/complications/drug therapy
MH  - Phosphodiesterase Inhibitors/*adverse effects/*therapeutic use
RF  - 82
EDAT- 2006/06/09 09:00
MHDA- 2007/05/10 09:00
CRDT- 2006/06/09 09:00
PHST- 2006/06/09 09:00 [pubmed]
PHST- 2007/05/10 09:00 [medline]
PHST- 2006/06/09 09:00 [entrez]
AID - 3901491 [pii]
AID - 10.1038/sj.ijir.3901491 [doi]
PST - ppublish
SO  - Int J Impot Res. 2007 Mar-Apr;19(2):139-48. doi: 10.1038/sj.ijir.3901491. Epub 
      2006 Jun 8.